Thus, it is essential to discover a novel target and available predictive biomarker to stratify patients who may benefit from immunotherapy in cervical cancer, such as P-selectin glycoprotein ligand-1 (PSGL-1). This evidence concerns the gene SELPLG and cervical carcinoma.